Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19
Masaya Sugiyama, Noriko Kinoshita, Satoshi Ide, Hidetoshi Nomoto, Takato Nakamoto, Sho Saito, Masahiro Ishikane, Satoshi Kutsuna, Kayoko Hayakawa, Masao Hashimoto, Manabu Suzuki, Shinyu Izumi, Masayuki Hojo, K. Tsuchiya, Hiroyuki Gatanaga, Jin Takasaki, Masahide Usami, Toshikazu Kano, Hidekatsu Yanai, Nao Nishida, Tatsuya Kanto, Haruhito Sugiyama, Norio Ohmagari, Masashi Mizokami
Topics & Concepts
BiologyCoronavirus disease 2019 (COVID-19)DiseasePredictive marker2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BetacoronavirusVirologyCCL17ImmunologyInternal medicineInflammationGeneticsChemokineInfectious disease (medical specialty)CancerMedicineCXCL10OutbreakCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19